Martins CP - Search Results

1

Modelling Myc inhibition as a cancer therapy.

Soucek L, Whitfield J, Martins CP, Finch AJ, Murphy DJ, Sodir NM, Karnezis AN, Swigart LB, Nasi S, Evan GI. Soucek L, et al. Among authors: martins cp. Nature. 2008 Oct 2;455(7213):679-83. doi: 10.1038/nature07260. Epub 2008 Aug 17. Nature. 2008. PMID: 18716624 Free PMC article.

2

Selective activation of p53-mediated tumour suppression in high-grade tumours.

Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, Martins CP. Junttila MR, et al. Among authors: martins cp. Nature. 2010 Nov 25;468(7323):567-71. doi: 10.1038/nature09526. Nature. 2010. PMID: 21107427 Free PMC article.

3

Modeling the therapeutic efficacy of p53 restoration in tumors.

Martins CP, Brown-Swigart L, Evan GI. Martins CP, et al. Cell. 2006 Dec 29;127(7):1323-34. doi: 10.1016/j.cell.2006.12.007. Epub 2006 Dec 21. Cell. 2006. PMID: 17182091 Free article.

4

Validation of MdmX as a therapeutic target for reactivating p53 in tumors.

Garcia D, Warr MR, Martins CP, Brown Swigart L, Passegué E, Evan GI. Garcia D, et al. Among authors: martins cp. Genes Dev. 2011 Aug 15;25(16):1746-57. doi: 10.1101/gad.16722111. Genes Dev. 2011. PMID: 21852537 Free PMC article.

5

Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy.

Evan GI, Christophorou M, Lawlor EA, Ringshausen I, Prescott J, Dansen T, Finch A, Martins C, Murphy D. Evan GI, et al. Cold Spring Harb Symp Quant Biol. 2005;70:263-73. doi: 10.1101/sqb.2005.70.054. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869762 Review.

6

The ERBB network facilitates KRAS-driven lung tumorigenesis.

Kruspig B, Monteverde T, Neidler S, Hock A, Kerr E, Nixon C, Clark W, Hedley A, Laing S, Coffelt SB, Le Quesne J, Dick C, Vousden KH, Martins CP, Murphy DJ. Kruspig B, et al. Among authors: martins cp. Sci Transl Med. 2018 Jun 20;10(446):eaao2565. doi: 10.1126/scitranslmed.aao2565. Sci Transl Med. 2018. PMID: 29925636 Free PMC article.

7

Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.

Kerr EM, Gaude E, Turrell FK, Frezza C, Martins CP. Kerr EM, et al. Among authors: martins cp. Nature. 2016 Mar 3;531(7592):110-3. doi: 10.1038/nature16967. Epub 2016 Feb 24. Nature. 2016. PMID: 26909577 Free PMC article.

8

Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress.

Farkas C, Martins CP, Escobar D, Hepp MI, Castro AF, Evan G, Gutiérrez JL, Warren R, Donner DB, Pincheira R. Farkas C, et al. Among authors: martins cp. PLoS One. 2013 Sep 6;8(9):e73817. doi: 10.1371/journal.pone.0073817. eCollection 2013. PLoS One. 2013. PMID: 24040083 Free PMC article.

9

Exploring the role of stromal osmoregulation in cancer and disease using executable modelling.

Shorthouse D, Riedel A, Kerr E, Pedro L, Bihary D, Samarajiwa S, Martins CP, Shields J, Hall BA. Shorthouse D, et al. Among authors: martins cp. Nat Commun. 2018 Aug 1;9(1):3011. doi: 10.1038/s41467-018-05414-y. Nat Commun. 2018. PMID: 30069015 Free PMC article.

10

Metabolic rewiring in mutant Kras lung cancer.

Kerr EM, Martins CP. Kerr EM, et al. Among authors: martins cp. FEBS J. 2018 Jan;285(1):28-41. doi: 10.1111/febs.14125. Epub 2017 Jun 22. FEBS J. 2018. PMID: 28570035 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

104 results

Search Page

Filters